146 related articles for article (PubMed ID: 2153905)
1. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
3. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.
Deffie AM; Batra JK; Goldenberg GJ
Cancer Res; 1989 Jan; 49(1):58-62. PubMed ID: 2535693
[TBL] [Abstract][Full Text] [Related]
4. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
5. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
6. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
9. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
10. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
11. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
12. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
[TBL] [Abstract][Full Text] [Related]
13. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
15. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
16. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Friche E; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
[TBL] [Abstract][Full Text] [Related]
17. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
19. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.
Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A
Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells.
Deffie AM; Bosman DJ; Goldenberg GJ
Cancer Res; 1989 Dec; 49(24 Pt 1):6879-82. PubMed ID: 2555055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]